Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update

Journal of Human Hypertension volume 21, pages 699–708 (2007)Cite this article

Abstract

Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. It is a prodrug that is hydrolysed in the gut into its active metabolite, olmesartan (RNH-6270). Olmesartan is highly selective for the Ang II type 1 receptor (AT1) to which it binds completely and insurmountably and has very little affinity for the other receptor subtypes AT2 and AT4. After oral administration, in animals and humans, it achieves a maximal blood drug concentration within a maximal time of approximately 2 h. It is then slowly eliminated in the urine and faeces. His half-life is approximately 13 h, which makes it suitable for once-daily administration. Olmesartan medoxomil given orally in single daily doses of 20–40 mg has demonstrated significant blood pressure (BP) lowering effects in hypertensive patients. A medline search for the preparation of this manuscript was conducted and revealed 128 references, from 2000 to 2007. Of these, only 16 well-designed prospective clinical trials were selected. The remaining were either animal studies, reviews or studies in progress. In well-designed clinical trials, olmesartan medoxomil has demonstrated similar antihypertensive actions to the other antihypertensive drugs, as well as other members of its class given the highest recommended doses. In addition, the BP lowering effect of olmesartan, like the other members of its class, is greatly enhanced in combination with a diuretic. Its safety profile is similar to the other ARBs and no different than placebo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Neutel JM . Clinical studies of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87 (8A): 37C–43C.

    Article  CAS  Google Scholar 

  2. Chrysant SG, Chrysant GS . Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Expert Opin Pharmacother 2004; 5: 657–667.

    Article  CAS  Google Scholar 

  3. Puchler K, Laeis P, Stumpe KO . Blood pressure response, but not adverse event incidence correlates with dose of angiotensin II antagonist. J Hypertens 2001; 19 (Suppl 1): S41–S48.

    Article  CAS  Google Scholar 

  4. Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN . Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002; 4: 325–331.

    Article  CAS  Google Scholar 

  5. Brunner HR, Nussberger J . Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1 receptor antagonist. J Hypertens 2001; 19 (Suppl 1): S15–S20.

    Article  CAS  Google Scholar 

  6. Ball KJ, Williams PA, Stumpe KO . Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens 2001; 19 (Suppl 1): S49–S56.

    Article  CAS  Google Scholar 

  7. Stumpe KO, Ludwig M . Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002; 16 (Suppl 2): S24–S28.

    Article  CAS  Google Scholar 

  8. Chrysant SG, Marbury TC, Robinson TD . Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–432.

    Article  CAS  Google Scholar 

  9. Chrysant SG, Weber MA, Wang AC, Hinman DJ . Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004; 17: 252–259.

    Article  CAS  Google Scholar 

  10. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J . Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–291.

    Article  CAS  Google Scholar 

  11. Smith DH, Dubiel R, Jones M . Use 24-h ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan and irbesartan. Am J Cardiovasc Drugs 2005; 5: 41–50.

    Article  CAS  Google Scholar 

  12. Stumpe KO . Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26 (Suppl A): A33–37.

    Article  CAS  Google Scholar 

  13. Brunner HR, Stumpe KO, Januszewicz A . Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-h ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest 2003; 23: 419–430.

    Article  CAS  Google Scholar 

  14. Giles TD, Oparil S, Silfani TN, Wang A, Walker JF . Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens 2007; 9: 187–195.

    Article  CAS  Google Scholar 

  15. Koike H, Sada T, Mizuno M . In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens 2001; 19 (Suppl 1): S3–S14.

    Article  CAS  Google Scholar 

  16. Schwocho LR, Masonson HN . Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. J Clin Pharmacol 2001; 41: 515–527.

    Article  CAS  Google Scholar 

  17. Warner GT, Jarvis B . Olmesartan medoxomil. Drugs 2002; 62: 1345–1353.

    Article  CAS  Google Scholar 

  18. Mire DE, Silfani TN, Pugsley MK . A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005; 46: 585–593.

    Article  CAS  Google Scholar 

  19. Von Bergman K, Laeis P, Püchler K, Sudhop T, Schwocho LR, Gonzales L . Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens 2001; 19 (Suppl 1): S38–S40.

    Google Scholar 

  20. Laeis P, Püchler K, Kirch W . The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens 2001; 19 (Suppl 1): S21–S32.

    Article  CAS  Google Scholar 

  21. Mizuno M, Sada T, Ikeda W, Fukuda N, Myamoto M, Yanagisawa H et al. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist. Eur J Pharmacol 1995; 285: 181–188.

    Article  CAS  Google Scholar 

  22. Koike H . New pharmacologic aspects of CS-866, the newest angiotensin II receptor antagonist. Am J Cardiol 2001; 87: 33–36.

    Article  CAS  Google Scholar 

  23. Miyazaki M, Takai S . Antiatherosclerotic efficacy of olmesartan. J Hum Hypertens 2002; 16 (Suppl 2): S7–S12.

    Article  CAS  Google Scholar 

  24. Takai S, Jin D, Sakaguchi M, Miyazaki M . Chymase-dependent angiotensin II formation in human vascular tissue. Circulation 1999; 100: 654–658.

    Article  CAS  Google Scholar 

  25. Ihara M, Urata H, Kinsoshita A, Suzumiya J, Sasaguri M, Kikuchi M et al. Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension 1999; 33: 1399–1405.

    Article  CAS  Google Scholar 

  26. Hollenberg NK, Fisher ND, Price DA . Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387–392.

    Article  CAS  Google Scholar 

  27. Chrysant SG . Vascular remodeling: the role of angiotensin converting enzyme inhibitors. Am Heart J 1998; 135: S21–S30.

    Article  CAS  Google Scholar 

  28. Chrysant SG, Marbury TC, Silfani TN . Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006; 11: 135–141.

    Article  Google Scholar 

  29. Sellin L, Stegbauer J, Laeis P, Rump LC . Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005; 23: 2083–2092.

    Article  CAS  Google Scholar 

  30. Fogari R, Zoppi A, Mugellini A, Preti P, Destro M, Rinaldi A et al. Hydrocholorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006; 23: 680–695.

    Article  CAS  Google Scholar 

  31. Chrysant SG, Dubiel R, Walker F, Izzo J . Efficacy of olmesartan medoxomil (OM) and hydrochlorothiazide (HCTZ) in achieving blood pressure goals in patients with stage 2 systolic hypertension: Effect of Body Mass Index (BMI). J Clin Hypertens (Abstr) 2006; 8: A136.

    Google Scholar 

  32. Chrysant SG, Dubiel R, Walker F, Izzo J . Efficacy of olmesartan medoxomil (OM) and OM/Hydrochlorothiazide (HCTZ) in achieving blood pressure goals in hypertensive patients with stage 2 systolic hypertension: Effects in non-black patients. J Clin Hypertens (Abstr) 2006; 8: A136.

    Google Scholar 

  33. Izzo JL, Neutel JM, Silfani T, Dubiel R, Walker F . Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: Results of an open-label titration study. J Clin Hypertens 2007; 9: 36–44.

    Article  CAS  Google Scholar 

  34. Izzo JL, Neutel JM, Silfani T, Walker F . Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens 2007; 9: 45–48.

    Article  CAS  Google Scholar 

  35. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. The JNC-7 report. JAMA 2003; 289: 2560–2571.

    Article  CAS  Google Scholar 

  36. American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27 (Suppl. 1): S65–S67.

    Google Scholar 

  37. Chrysant SG, Chrysant GS . The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens 2006; 8: 261–268.

    Article  CAS  Google Scholar 

  38. Malmqvist K, Ohman KP, Lind L, Nystrom F, Kahan T . Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SYLVHIA). J Cardiovasc Pharmacol 2003; 42: 719–726.

    Article  CAS  Google Scholar 

  39. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, deFaire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint (LIFE) reduction hypertension study: a randomized trial against atenolol. Lancet 2002; 359: 995–1003.

    Article  CAS  Google Scholar 

  40. Pitt B, Pool-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomized trial: the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582–1587.

    Article  CAS  Google Scholar 

  41. Dicstein K, Kjekshus J, the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the OPTIMAAL randomized trial. Lancet 2002; 360: 752–760.

    Article  Google Scholar 

  42. Cohn JN, Tognoni G . Valsartan Heart Failure Trial investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–1675.

    Article  CAS  Google Scholar 

  43. Pfeffer MA, McMurray JT, Velasquez EJ, Rouleau JL, Kober L, Maggioni AP, et al., for the Valsartan Acute Myocardial Infarction Trial (VALIANT) investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction or both. N Engl J Med 2003; 349: 1893–1906.

    Article  CAS  Google Scholar 

  44. Pfeffer MA, Swedberg K, Granger CD, Held P, McMurray JJ, Michelson EL et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003; 362: 759–766.

    Article  CAS  Google Scholar 

  45. Viberti G, Wheeldon NM, for the Micro-Albuminuria Reduction with VALsartan (MARVAL) Study Investigators. Micro-albuminuria reduction with valsartan in patients with type-2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672–678.

    Article  CAS  Google Scholar 

  46. Parving HH, Lehert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type-2 diabetes. N Engl J Med 2001; 385: 870–878.

    Article  Google Scholar 

  47. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type-2 diabetes. N Engl J Med 2001; 345: 851–860.

    Article  CAS  Google Scholar 

  48. Brenner BM, Cooper ME, Dezeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type-2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.

    Article  CAS  Google Scholar 

  49. Chrysant SG . Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today 2004; 40: 791–801.

    Article  CAS  Google Scholar 

  50. Chrysant SG . Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin converting enzyme inhibitors. J Hum Hypertens 2005; 19: 923–931.

    Article  CAS  Google Scholar 

  51. Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: A Losartan Intervention For Endpoint (LIFE) sub-study. JAMA 2002; 288: 1491–1498.

    Article  CAS  Google Scholar 

  52. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

    Article  CAS  Google Scholar 

  53. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B et al. Stroke prevention with the angiotensin II type 1 receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175–1180.

    CAS  PubMed  Google Scholar 

  54. Schrader J, Luders S, Kulschewski A, Hammersen F, Zuchner C, Venneklaas U et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized control study (MOSES). Stroke 2005; 36: 1218–1226.

    Article  CAS  Google Scholar 

  55. Mochizuki S, Dahlof B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 360: 1431–1439.

    Article  Google Scholar 

  56. Julius S, Kjeldsen SE, Weber MA, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–2031.

    Article  CAS  Google Scholar 

  57. Morawietz H, Ruecksloss U, Niemann B, Duerschmidt N, Galle J, Hakim K et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100: 899–902.

    Article  CAS  Google Scholar 

  58. Miyazaki M, Takai S . Antiatherosclerotic efficacy of olmesartan. J Hum Hypertens 2002; 16 (Suppl. 2): S7–S12.

    Article  CAS  Google Scholar 

  59. Inukai T, Yoshida N, Wakabayashi S, Inukai Y, Matsutomo R, Takanashi K et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers effectively and directly potentiate superoxide scavenging by polymorphonuclear-leukocytes from patients with type 2 diabetes mellitus. Am J Med Sci 2005; 329: 222–227.

    Article  Google Scholar 

  60. Kurtz TW, Pravenec M . Antidiabetic mechanisms and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253–2261.

    Article  CAS  Google Scholar 

  61. Guerra-Cuesta JL, Monton M, Rodriguez-Feo JA, Jimenez AM, Gonzalez-Fernandez F, Rico LA et al. Effect of losartan on human platelet activation. J Hypertens 1999; 17: 447–452.

    Article  CAS  Google Scholar 

  62. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832–1839.

    Article  CAS  Google Scholar 

  63. Wachtel K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B et al. Angiotensin II receptor blockade reduces new onset atrial fibrillation and subsequent stroke compared to atenolol. J Am Coll Cardiol 2005; 45: 712–719.

    Article  Google Scholar 

  64. Hasford J, Mimran A, Simons WR . A population-based European cohort study of persistence within newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–575.

    Article  CAS  Google Scholar 

  65. Marentette MA, Gerth WC, Billings DK, Zarnke KB . Antihypertensive persistence and drug class. Can J Cardiol 2002; 18: 649–656.

    CAS  PubMed  Google Scholar 

  66. Yusuf S . From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002; 89: 18A–25A.

    Article  Google Scholar 

  67. Diener HC . Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS): rationale and design. Cerebrovasc Dis 2000; 10: 147–150.

    Article  Google Scholar 

  68. Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E et al. Preventing micro-albuminuria in patients with diabetes: rationale and design of the Randomized Olmesartan and Diabetes Micro-albuminuria Prevention (ROADMAP) study. J Hypertens 2006; 24: 403–408.

    Article  CAS  Google Scholar 

  69. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H . Chronic angiotensin II receptor blockade reduces intrarenal vascular resistance in patients with type 2 diabetes. J Am Soc Nephrol 2005; 16: 1135–1140.

    Article  CAS  Google Scholar 

  70. Mizuno M, Sada T, Kato M, Koike H . Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes. Hypertens Res 2002; 25: 271–278.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oklahoma Cardiovascular and Hypertension Center, University of Oklahoma School of Medicine, Oklahoma City, OK, USA

    S G Chrysant & M Shiraz

  2. Division of Cardiology, Southwestern University School of Medicine, Dallas, TX, USA

    B Dimas

Authors
  1. S G Chrysant
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B Dimas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Shiraz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S G Chrysant.

Additional information

Disclosures

No financial or editorial support was provided for the preparation of this manuscript. There are no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chrysant, S., Dimas, B. & Shiraz, M. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. J Hum Hypertens 21, 699–708 (2007). https://doi.org/10.1038/sj.jhh.1002241

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1002241

Keywords

Search

Advanced search

Quick links